4.6 Article

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn

期刊

ANTIBIOTICS-BASEL
卷 11, 期 5, 页码 -

出版社

MDPI
DOI: 10.3390/antibiotics11050618

关键词

burns; critical illness; pharmacokinetics; piperacillin; tazobactam

资金

  1. WRAIR/USUHS Clinical Pharmacology Fellowship [P8]

向作者/读者索取更多资源

This study investigated the pharmacokinetics of pip-tazo in critically ill patients and found no significant differences in volume of distribution or clearance between burn and non-burn patients. However, considerations of pharmacodynamics and augmented renal clearance in burn patients may lead to the choice of higher doses. Continuous infusions of 13.5-18 g pip-tazo per day are recommended for critically ill patients with normal kidney function, but higher doses may be required for specific cases.
Critical illness caused by burn and sepsis is associated with pathophysiologic changes that may result in the alteration of pharmacokinetics (PK) of antibiotics. However, it is unclear if one mechanism of critical illness alters PK more significantly than another. We developed a population PK model for piperacillin and tazobactam (pip-tazo) using data from 19 critically ill patients (14 non-burn trauma and 5 burn) treated in the Military Health System. A two-compartment model best described pip-tazo data. There were no significant differences found in the volume of distribution or clearance of pip-tazo in burn and non-burn patients. Although exploratory in nature, our data suggest that after accounting for creatinine clearance (CrCl), doses would not need to be increased for burn patients compared to trauma patients on consideration of PK alone. However, there is a high reported incidence of augmented renal clearance (ARC) in burn patients and pharmacodynamic (PD) considerations may lead clinicians to choose higher doses. For critically ill patients with normal kidney function, continuous infusions of 13.5-18 g pip-tazo per day are preferable. If ARC is suspected or the most stringent PD targets are desired, then continuous infusions of 31.5 g pip-tazo or higher may be required. This approach may be reasonable provided that therapeutic drug monitoring is enacted to ensure pip-tazo levels are not supra-therapeutic.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据